Sutent (sunitinib malate) - Important Safety Information from Pfizer as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 08/12/2010


Problem Or Issue:
Important safety information communication from Pfizer on Osteonecrosis of the jaw in cancer patients treated with sunitinib (Sutent) and concomitant or previous use of biphosphonates.

Important Safety Information - Sutent (sunitinib malate)

« Back